← Patent-cliff monitor small molecule REZLIDHIA OLUTASIDENIB
Loss of exclusivity November 2039 latest FDA-listed patent expiry
Drug detail Brand name REZLIDHIA Active ingredient OLUTASIDENIB Strength 150MG Dosage form CAPSULE Route ORAL Modality Small molecule FDA approval December 2022 Marketing status RX
Listed patents Patent Expires Type 11723905 November 2039 product 11738018 July 2039 use U-3684 11013734 May 2039 use U-3495 11013733 May 2039 use U-3496 11497743 May 2039 use U-3495 11376246 May 2039 use U-3495 10532047 May 2039 substance 12053463 May 2039 substance, product 10959994 May 2039 product 11498913 September 2035 product 10414752 September 2035 product 12275715 September 2035 substance, product 10550098 September 2035 product 9834539 September 2035 substance, product
Regulatory exclusivity Code Expires ODE-413 December 2029 NCE December 2027
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.